Your browser doesn't support javascript.
loading
Application of HDR-CRISPR/Cas9 and Erythrocyte Binding for Rapid Generation of Recombinant Turkey Herpesvirus-Vectored Avian Influenza Virus Vaccines.
Chang, Pengxiang; Ameen, Faisal; Sealy, Joshua E; Sadeyen, Jean-Remy; Bhat, Sushant; Li, Yongqing; Iqbal, Munir.
Afiliação
  • Chang P; Avian Influenza Group, The Pirbright Institute, Pirbright, Woking GU24 0NF, UK.
  • Ameen F; Department of Microbiology, University of Veterinary and Animal Sciences Lahore 54000, Pakistan.
  • Sealy JE; Avian Influenza Group, The Pirbright Institute, Pirbright, Woking GU24 0NF, UK.
  • Sadeyen JR; Avian Influenza Group, The Pirbright Institute, Pirbright, Woking GU24 0NF, UK.
  • Bhat S; Avian Influenza Group, The Pirbright Institute, Pirbright, Woking GU24 0NF, UK.
  • Li Y; Institute of Animal Husbandry and Veterinary Medicine, Beijing Academy of Agricultural and Forestry Sciences, Beijing 100097, China.
  • Iqbal M; Sino-UK Joint Laboratory for the Prevention & Control of Infectious Diseases in Livestock and Poultry, Institute of Animal Husbandry and Veterinary Medicine, Beijing 100097, China.
Vaccines (Basel) ; 7(4)2019 Nov 22.
Article em En | MEDLINE | ID: mdl-31766655
Avian influenza viruses (AIVs) are highly contagious and have caused huge economical loss to the poultry industry. AIV vaccines remain one of the most effective methods of controlling this disease. Turkey herpesvirus (HVT) is a commonly used live attenuated vaccine against Marek's disease; it has also been used as a viral vector for recombinant AIV vaccine development. The clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 system is a gene editing tool which, in vaccinology, has facilitated the development of recombinant DNA viral-vectored vaccines. Here, we utilize homology-directed repair (HDR) for the generation of a HVT-H7N9 HA bivalent vaccine; a H7N9 HA expression cassette was inserted into the intergenic region between UL45 and UL46 of HVT. To optimize the selection efficiency of our bivalent vaccine, we combined CRISPR/Cas9 with erythrocyte binding to rapidly generate recombinant HVT-H7HA candidate vaccines.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article